-
Product Name
Anti-CD70 antibody
- Documents
-
Description
Rabbit Polyclonal to Mouse CD70
-
Tested applications
WB
-
Species reactivity
Mouse CD70 / CD27L / TNFSF7
-
Alternative names
CD27LG antibody; CD27L antibody; CD27LG antibody; CD70 antibody; TNFSF7 antibody; Cd27l antibody; Tnfsf7 antibody; CD27L antibody; CD27LG antibody; TNFSF7 antibody; Cd27l antibody; CD27LG antibody; Tnfsf7 antibody
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with a synthetic peptide corresponding to the N-terminus of the Mouse CD70 / CD27L / TNFSF7, and purified by antigen affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 5-20 μg/ml
-
Validations
Mouse CD70/CD27L/TNFSF7 Western blot (WB) 14923
-
Background
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Immune Checkpoint
Immune Checkpoint Proteins
Immune Checkpoint Targets Co-stimulatory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"